Shares of Juno Therapeutics Inc (NASDAQ:JUNO) saw unusually-strong trading volume on Thursday . Approximately 4,202,753 shares were traded during trading, an increase of 17% from the previous session’s volume of 3,606,584 shares.The stock last traded at $29.14 and had previously closed at $30.42.

Several equities analysts recently issued reports on JUNO shares. Morgan Stanley raised their price objective on Juno Therapeutics from $48.00 to $50.00 in a research note on Friday, April 8th. Vetr cut Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $53.00 price objective on the stock. in a research note on Monday, June 6th. Leerink Swann restated a “buy” rating on shares of Juno Therapeutics in a research note on Thursday. Zacks Investment Research cut Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, April 15th. Finally, FBR & Co restated a “buy” rating on shares of Juno Therapeutics in a research note on Monday, June 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Juno Therapeutics presently has a consensus rating of “Buy” and an average target price of $53.11.

The stock has a 50-day moving average price of $40.01 and a 200-day moving average price of $38.03. The stock’s market cap is $2.96 billion.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.26. The firm earned $9.80 million during the quarter, compared to analyst estimates of $4.83 million. During the same quarter in the previous year, the company posted ($0.30) EPS. On average, equities research analysts anticipate that Juno Therapeutics Inc will post ($2.28) EPS for the current year.

In other news, CFO Steve Harr sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $43.32, for a total transaction of $1,299,600.00. Following the sale, the chief financial officer now directly owns 716,052 shares in the company, valued at $31,019,372.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Hans Edgar Bishop sold 90,750 shares of the business’s stock in a transaction that occurred on Thursday, June 9th. The shares were sold at an average price of $46.42, for a total value of $4,212,615.00. Following the sale, the chief executive officer now owns 2,704,609 shares in the company, valued at $125,547,949.78. The disclosure for this sale can be found here.

Several hedge funds have recently added to or reduced their stakes in the stock. BBR Partners LLC purchased a new stake in Juno Therapeutics during the fourth quarter worth about $1,539,000. BNP Paribas Arbitrage SA boosted its stake in Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock worth $2,252,000 after buying an additional 10,884 shares in the last quarter. Stevens Capital Management LP purchased a new stake in Juno Therapeutics during the fourth quarter worth about $2,315,000. Swiss National Bank purchased a new stake in Juno Therapeutics during the fourth quarter worth about $2,603,000. Finally, ProShare Advisors LLC purchased a new stake in Juno Therapeutics during the fourth quarter worth about $3,674,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.